February 21, 2001

Accuracy of Positron Emission Tomography for Diagnosis of Pulmonary Nodules and Mass LesionsA Meta-analysis

Author Affiliations

Author Affiliations: Health Services Research and Development Service (Drs Gould and Owens) and Medical Service (Dr Kuschner), Veterans Affairs Palo Alto Health Care System, and the Veterans Affairs Cooperative Studies Program (Mss Maclean and Rydzak), Palo Alto, Calif; and the Division of Pulmonary and Critical Care Medicine (Drs Gould and Kuschner), Department of Health Research and Policy (Drs Gould and Owens), and Center for Primary Care and Outcomes Research (Drs Gould and Owens and Mss Maclean and Rydzak), Stanford University School of Medicine, Stanford, Calif.

JAMA. 2001;285(7):914-924. doi:10.1001/jama.285.7.914

Context Focal pulmonary lesions are commonly encountered in clinical practice, and positron emission tomography (PET) with the glucose analog 18-fluorodeoxyglucose (FDG) may be an accurate test for identifying malignant lesions.

Objective To estimate the diagnostic accuracy of FDG-PET for malignant focal pulmonary lesions.

Data Sources Studies published between January 1966 and September 2000 in the MEDLINE and CANCERLIT databases; reference lists of identified studies; abstracts from recent conference proceedings; and direct contact with investigators.

Study Selection Studies that examined FDG-PET or FDG with a modified gamma camera in coincidence mode for diagnosis of focal pulmonary lesions; enrolled at least 10 participants with pulmonary nodules or masses, including at least 5 participants with malignant lesions; and presented sufficient data to permit calculation of sensitivity and specificity were included in the anaylsis.

Data Extraction Two reviewers independently assessed study quality and abstracted data regarding prevalence of malignancy and sensitivity and specificity of the imaging test. Disagreements were resolved by discussion.

Data Synthesis We used a meta-analytic method to construct summary receiver operating characteristic curves. Forty studies met inclusion criteria. Study methodological quality was fair. Sample sizes were small and blinding was often incomplete. For 1474 focal pulmonary lesions of any size, the maximum joint sensitivity and specificity (the upper left point on the receiver operating characteristic curve at which sensitivity and specificity are equal) of FDG-PET was 91.2% (95% confidence interval, 89.1%-92.9%). In current practice, FDG-PET operates at a point on the summary receiver operating characteristic curve that corresponds approximately to a sensitivity and specificity of 96.8% and 77.8%, respectively. There was no difference in diagnostic accuracy for pulmonary nodules compared with lesions of any size (P = .43), for semiquantitative methods of image interpretation compared with qualitative methods (P = .52), or for FDG-PET compared with FDG imaging with a modified gamma camera in coincidence mode (P = .19).

Conclusions Positron emission tomography with 18-fluorodeoxyglucose is an accurate noninvasive imaging test for diagnosis of pulmonary nodules and larger mass lesions, although few data exist for nodules smaller than 1 cm in diameter. In current practice, FDG-PET has high sensitivity and intermediate specificity for malignancy.